

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



160 Health International Limited

健康 160 国际有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2656)

**VOLUNTARY ANNOUNCEMENT
VOLUNTARY EXTENSION OF LOCK-UP PERIOD GIVEN BY
THE CONTROLLING SHAREHOLDERS**

This announcement is made by 160 Health International Limited (the “**Company**”) on a voluntary basis to inform its shareholders and potential investors about an extension of lock-up period given by its controlling shareholders, namely Mr. Luo Ningzheng, LNZ Management Limited and Luo Holdings Limited.

Reference is made to the prospectus of the Company dated September 9, 2025 (the “**Prospectus**”). Unless otherwise defined, terms used herein shall have the same meaning as defined in the Prospectus.

As disclosed in the Prospectus, pursuant to Rule 10.07 of the Listing Rules, each of the Controlling Shareholders has undertaken that except pursuant to the Global Offering, he/it shall not: (a) in the period commencing on the date of the Prospectus and ending on the date which is six months from the Listing Date (the “**First Six-Month Period**”), either directly or indirectly, dispose of, nor enter into any agreement to dispose of or otherwise create any options, rights, interests or encumbrances in respect of, any of the securities of the Company that it is shown to beneficially own in the Prospectus (the “**Relevant Shares**”) (the “**First Lock-up Undertaking**”); or (b) in the period of six months from the expiry of the First Six-Month Period (the “**Second Six-Month Period**”), either directly or indirectly, dispose of, nor enter into any agreement to dispose of or otherwise create any options, rights, interests or encumbrances in respect of, any of the Relevant Shares if, immediately following such disposal or upon the exercise or enforcement of such options, rights, interests or encumbrances, it will cease to be a controlling shareholder (as defined in the Listing Rules) of the Company. Further, each of the Controlling Shareholders has provided similar lock-up undertaking to the Company and the Underwriters, among others, (i) not to sell, or otherwise transfer or dispose of, either directly or indirectly, any

Relevant Shares of the Company during the First Six-Month Period, or (ii) enter into any of the transactions specified in (i) above during the Second Six-Month Period if, immediately following any such transaction, it/he will cease to be a controlling shareholder (as defined in the Listing Rules) of the Company.

The Company has been informed by the Controlling Shareholders that they have voluntarily extended the First Lock-up Undertaking to the Company for another six months up to September 16, 2026 (inclusive), during which it will not, either directly or indirectly, sell, or otherwise transfer or dispose of any the Relevant Shares of the Company in any manner. As at the date of this announcement, the total number of the Relevant Shares is 102,912,905, representing approximately 30.59% of the total issued shares of the Company. After the aforementioned voluntary extension, the lock-up arrangements applicable to the Controlling Shareholders will be the same as those applicable to all other Shareholders who are subject to a lock-up undertaking.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
160 Health International Limited
Mr. LUO Ningzheng
*Chairman of the Board, Executive Director
and Chief Executive Officer*

Hong Kong, March 13, 2026

As of the date of this announcement, the Board comprises (i) Mr. LUO Ningzheng, Mr. JI Cuilin, Mr. HUANG Lang and Mr. WANG Lifa as executive Directors; (ii) Mr. LIU Haibin and Ms. SUN Meng as non-executive Directors; and (iii) Mr. WANG Huan, Dr. XU Weiguo and Dr. FAN Ming as independent non-executive Directors.